Efficacy of local versus systemic application of antibody-cytokine fusion proteins in tumor therapy

Clinical Cancer Research

Volumn 7, Issue 4, 2001, Pages 985-998

  Christ, Oliver ^a   Seiter, Simone ^b   Matzku, Siegfried ^c,d   Burger, Christa ^c   Zöller, Margot ^a,d  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

^c MERCK KGAA   (Germany)

^d UNIVERSITY OF KARLSRUHE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CD3 ANTIGEN; CYTOKINE; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; HYBRID PROTEIN; INTERLEUKIN 2; MONOCLONAL ANTIBODY; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; COLON CARCINOMA; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG ACCUMULATION; DRUG TUMOR LEVEL; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; LYMPHOCYTE PROLIFERATION; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIBODIES; CYTOKINES; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION ROUTES; HUMANS; IMMUNITY; INTERLEUKIN-2; MICE; MICE, SCID; NEOPLASMS, EXPERIMENTAL; RECOMBINANT FUSION PROTEINS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0034896595     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (68)

1. Future developments in the selectivity of anticancer agents: Drug delivery and molecular target strategies
2. Novel molecular and cellular strategies in cancer therapy
3. Current challenges in cancer gene therapy
4. Human tumor antigens recognized by T cells: New perspectives for anti-cancer vaccines
5. Tumor antigens discovery: Perspectives for cancer therapy
6. Dendritic cell vaccines for cancer immunotherapy
7. Functional properties of tumor-infiltrating and blood lymphocytes in patients with solid tumors: Effects of tumor cells and their supernatants on proliferative responses of lymphocytes
8. Tumor-reactive T cells accumulate in lung cancer tissue but fail to respond due to tumor cell derived factor
9. Targeting cancer therapy
10. Targeting of peripheral blood T lymphocytes
11. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies
12. New developments in the use of cytokines for cancer therapy
13. Recombinant interleukin-2-based treatments for advanced melanoma: The experience of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group
14. Vascular leak syndrome: A side effect of immunotherapy
15. Interleukin 1 trials in cancer patients: A review of the toxicity, antitumor, and hematopoietic effects
16. Mechanisms of leukocyte-mediated tissue injury induced by interleukin-2
17. Single-chain Fv antibodies for targeting cancer therapy
18. Stimulation of T cell proliferation by a chimeric B7-2 antibody fusion protein specifically targeted to cells expressing the erbB2 proto-oncogene
19. Tumor-growth inhibition with bispecific antibody fragments in a syngeneic mouse melanoma model: The role of targeted T-cell co-stimulation via CD28
20. Human melanoma therapy in the SCID mouse: Targeting and activation of melanoma-specific cytotoxic T cells by bispecific antibody fragments is curative
21. Single-chain antibodies in pancreatic cancer
22. Impact of chimeric immune receptor extracellular protein domains on T cell function
23. Superantigen-targeted therapy: Phase I escalating repeat dose trial of the fusion protein PNU-214565 in patients with advanced gastrointestinal malignancies
24. Endothelial cells expressing an inflammatory phenotype are lysed by superantigen-targeted cytotoxic T cells
25. Perforin and IFN-γ are involved in the antitumor effects of antibody-targeted superantigens
26. Repeated treatment with antibody-targeted superantigens strongly inhibits tumor growth
27. Immunotherapy of human colon cancer by antibody-targeted superantigens
28. Superantigen-based immunotherapy: A Phase I trial of PNU-214565, a monoclonal antibody-staphylococcal enterotoxic A recombinant fusion protein, in advanced pancreatic and colorectal cancer
29. Targeting cytokines to tumors to induce active antitumor immune responses by recombinant fusion proteins
30. A recombinant antibody-interleukin 2 fusion protein suppresses growth of hepatic human neuroblastoma metastases in severe combined immunodeficiency mice
31. Eradication of human hepatic and pulmonary melanoma metastases in SCID mice by antibody-interleukin 2 fusion proteins
32. Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow
33. Eradication of established hepatic human neuroblastoma metastases in mice with severe combined immunodeficiency by antibody-targeted interleukin-2
34. Synergy between an antiangiogenic integrin αv antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases
35. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225
36. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy
37. Antigen expression of metastasizing and non-metastasizing human melanoma cells xenografted into nude mice
38. Melanocyte lineage specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes
39. Humanization of a mouse monoclonal antibody by CDR-grafting: The importance of framework residues on loop conformation
40. Isolation and expression of an altered mouse dihydrofolate reductase cDNA
41. Dendritic cells differentiated from human monocytes through a combination of IL-4. GM-CSF, and IFN-γ exhibit phenotype and function of blood dendritic cells
42. Immunobiology of human melanoma antigens MART-1 and gp100 and their use for immuno-gene therapy
43. In silico generation of tissue-specific and promiscuous HLA ligand databases using chips and virtual HLA class II matrices
44. Improved engraftment of human tumors in SCID mice pretreated with radiation and anti-asialo GM1
45. Suppression of a "recurrent" idiotype results in profound alterations of the whole B-cell compartment
46. Protein and cell membrane iodinations with a sparingly soluble chloramide, 1.3.4.6-tetrachloro-3a, 6a-diphenylglycoluril
47. Phase I and imaging trial of a monoclonal antibody directed against gastrin-releasing peptide in patients with lung cancer
48. The inflammatory cytokines. New developments in the pathophysiology and treatment of septic shock
49. DNA cancer vaccines: A gene gun approach
50. Cytokine-based gene therapy of human tumors. An overview
51. Tumor-targeted IL-2 amplifies T cell-mediated response induced by gene therapy with single-chain IL-12
52. An antibody-interleukin 2 fusion protein overcomes tumor heterogeneity by induction of a cellular immune response
53. Antibody targeted interleukin 2 stimulates T-cell killing of autologous tumor cells
54. A chimeric Lym-1/interleukin 2 fusion protein for increasing tumor vascular permeability and enhancing antibody uptake
55. Activation of human effector cells by a tumor reactive recombinant anti-ganglioside GD2 interleukin-2 fusion protein
56. Tumor necrosis factor in man: Clinical and biological observations
57. Tumor necrosis factor α and toxicology
58. Tumour necrosis factor: Strategies for improving the therapeutic index
59. Tumor necrosis factor: Function, release, and clearance
60. Tumor necrosis factor as an antineoplastic agent: Pitfalls and promises
61. Effector cell targeting by bispecific antibodies in the therapy of human malignant melanoma: Evaluation in the SCID mouse model
62. Antibody-IL-12 fusion proteins are effective in SCID mouse models of prostate and colon carcinoma metastases
63. Involvement of B lymphocytes in the growth inhibition of human pulmonary melanoma metastases in athymic nu/nu mice by an antibody-lymphotoxin fusion protein
64. Enhancing effect of tumor necrosis factor (TNF)-α, but not IFN-γ, on the tumor-specific cytotoxicity of γ/δ T cells from glioblastoma patients
65. Tumor necrosis factor α-mediated tumor regression by the in vivo transfer of genes into the artery that leads to tumors
66. Regression of human breast cancer xenografts in response to intralesional treatment with interferons α and γ potentiated by tumor necrosis factor
67. Biological response modulation by tumor necrosis factor α (TNF α) in a phase Ib trial in cancer patients
68. Retroviral vector-mediated transfer of the tumor necrosis factor α gene into human cancer cells restores an apoptotic cell death program and induces a bystander-killing effect